Table 1.
Demographic and disease characteristics at vaccination, and prevaccination- and postvaccination GML in RA patients on different treatments and controls
|
Treatment groups |
Rituximab monotherapy |
Rituximab + MTX |
Abatacept (n = 17) |
Tocilizumab (n = 16) |
MTX |
Controls |
|---|---|---|---|---|---|---|
| |
|
|
|
|
(n = 85) |
(n = 86) |
| (n = 29) | (n = 26) | |||||
|
Female gender, % |
72% |
62% |
88% |
81% |
79% |
45% |
|
Age, years, mean (SD) (range) |
68.9 (9) (50 to 87) |
59.9 (12) (39 to 85) |
56.6 (13) (29 to 75) |
55.6 (12) (27 to 72) |
61.5 (14) (24 to 85) |
51.6 (12) (22 to 75) |
|
Disease duration, years mean (SD) (range) |
21.3 (14) (0 to 57) |
14.5 (12) (2 to 50) |
14.9 (2.9) (2 to 46) |
13.8 (12) (0 to 43) |
11.4 (10) (0 to 40) |
12.7 (12) (0 to 45) |
|
HAQ, 0 to 3 |
1.2 (0.8) |
1.1 (0.6) |
1.4 (0.6) |
1.5 (0.7) |
0.7 (0.6) |
0.5 (0.5) |
|
DAS, 0 to 7 |
3.9 (1.2) |
3.9 (1.1) |
4.9 (1.2) |
3.6 (1.7) |
3.7 (1.2) |
3.0 (1.1) |
|
Ongoing MTX, yes, % |
---- |
100% |
76% |
56% |
100% |
---- |
|
MTX mg/week, mean |
---- |
17.2 |
15.6 |
14.7 |
16.4 |
---- |
|
Ongoing prednisolone, yes, % |
55.2% |
65.4% |
70.0% |
53.3% |
31.3% |
6.2% |
|
Prednisolone, mg/week, mean |
30.9 |
35.4 |
32.7 |
27.5 |
14.0% |
2.2 |
|
CRP mg/L, mean |
15.8 |
6.4 |
9.7 |
3.9 |
8.9 |
7.7 |
|
TJC28, mean (range) |
3.5 (0 to 23) |
4.7 (0 to 19) |
8.2 (0 to 20) |
7.6 (0 to 28) |
2.8 (0 to 12) |
1.9 (0 to 18) |
|
SJC, mean (range) |
3.4 (0 to 15) |
3.9 (0 to 13) |
4.8 (0 to 12) |
5.1 (0 to 25) |
2.0 (0 to 11) |
0.4 (0 to 5) |
|
RF-positive, % |
93% |
89% |
88% |
81% |
78% |
NA |
|
Anti-CCP-positive, % |
86% |
92% |
82% |
63% |
75% |
NA |
|
Smoker, % |
14% |
31% |
19% |
14% |
19% |
12% |
|
IgG at vaccination, g/L, mean (SD) |
8.2 (2.9) |
8.0 (2) |
9.1 (1.9) |
8.7 (2.6) |
9.7 (2.5) |
9.9 (2.1) |
|
IgM at vaccination, g/L, mean (SD) |
0.8 (0.7) |
0.9 (0.5) |
1.3 (0.7) |
1.1 (0.5) |
1.1 (0.6) |
1.0 (0.6) |
|
IgA at vaccination, g/L, mean (SD) |
2.3 (1.3) |
2.4 (0.9) |
2.9 (1.3) |
2.5 (0.9) |
2.5 (1.1) |
2.5 (1.1) |
|
Pneumococcal vaccine previously, % |
24.1% |
23.1% |
11.8% |
6.3% |
10.6% |
1.2% |
|
Last biologic treatment before vaccination, days, mean (range) |
71 (0 to 501) |
102 (0 to 894) |
8 (0 to 26) |
7 (0 to 34) |
NA |
NA |
|
Prevaccination antibody levels for 6B, mg/L, GML (95% CI) |
0.3 (0.2-0.6) |
0.4 (0.2, 0.8) |
0.6 (0.3, 1.4) |
0.4 (1.0, 1) |
2.0 (1.4, 2.8) |
2.9 (2.1, 4.0) |
|
Postvaccination antibody levels for 6B, mg/L, GML (95% CI) |
0.4 (0.2-0.8) |
0.4 (0.2, 0.8) |
1.1 (0.4, 2.7) |
1.7 (0.5, 5.8) |
3.5 (2.5, 4.9) |
9.5 (6.7, 13.6) |
|
Prevaccination antibody levels for 23F, mg/L, GML (95% CI) |
0.2 (0.1, 0.4) |
0.3 (0.1, 0.5) |
0.4 (0.2, 0.9) |
0.2 (0.1, 0.5) |
0.7 (0.5, 1.1) |
0.97 (0.7, 1.4) |
| Postvaccination antibody levels for 23F, mg/L, GML (95% CI) | 0.3 (0.2, 0.6) | 0.4 (0.2, 0.8) | 1.1 (0.6, 2.3) | 2.2 (0.9-5.3) | 1.9 (1.4, 2.6) | 6.4 (4.5, 9.1) |
Controls were patients with spondyloarthropathy on non-steroidal anti-inflammatory drugs/analgesics. GML, geometric mean antibody levels; RA, rheumatoid arthritis; MXT, methotrexate; HAQ, health assessment questionnaire; DAS, disease activity score; TJC, tender joint count; SJC, swollen joint count; RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide antibody; NA, not applicable.